On October 1, 2018 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) reported that Alexis Peyroles, chief executive officer, will present an overview of the Company’s business and will be available to participate in one-on-one meetings with investors at the 18th Annual Biotech in Europe Investor Forum to be held Oct. 4-5, 2018, in Basel, Switzerland (Press release, OSE Immunotherapeutics, OCT 1, 2018, View Source [SID1234529791]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of OSE Immunotherapeutics’ presentation are as follows:

Date: Friday, Oct. 5, 2018

Time: 10:30 a.m. CET

Location: Track 1, Room Darwin, Congress Center Basel, Switzerland

The presentation will be webcast live and remain available for three months thereafter on: View Source